RCS - Aptamer Group PLC - New contract with Metir plc

AptamerAnnouncement

11/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250911:nRSK8688Ya&default-theme=true

RNS Number : 8688Y  Aptamer Group PLC  11 September 2025

 

11 September 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

New contract with Metir plc

Development of Optimer® binders for rapid Cryptosporidium detection in the
next-generation pathogen monitoring platform

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, is pleased to announce that it has
signed a new contract with Metir plc (AIM: MET), the leading global provider
of mobile and point-of-use water and environmental testing technology. The
agreement covers the development of Optimer® binders for the rapid detection
of Cryptosporidium parvum oocysts in Metir's Pathogen Detector platform.

Further to the Company's announcement on 14 June 2024 regarding collaboration
with Metir on pathogen detection, the new agreement involves the creation of
novel high-affinity binders for integration into Metir's real-time monitoring
device. This system is designed to provide continuous water quality monitoring
and early detection of contamination within minutes, compared with
conventional laboratory testing that can take several days.

The collaboration highlights the adaptability of Aptamer Group's Optimer®
technology in delivering robust, synthetic binders with high specificity and
stability for real-world deployment. Optimers offer a secure, scalable supply
chain and can be tailored for multiplexed detection of multiple pathogens,
expanding potential applications into broader environmental and healthcare
monitoring markets.

The staged programme will deliver feasibility, isolation and optimisation
work, with proof-of-concept data expected within three months. This represents
one of the final technical milestones to advance Metir's Pathogen Detector
beyond the prototype stage, with possible initial trials by UK water companies
anticipated once development is complete.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:

 

"We are pleased to be working with Metir on this important programme. Our
Optimer® technology is ideally suited for Cryptosporidium detection, and we
look forward to supporting the development of this pathogen monitoring
platform."

 

Bob Moore, Executive Chairman and Chief Executive Officer of Metir, said:

 

"This agreement marks another step forward in Metir's strategy to deliver
next-generation, real-time water monitoring solutions. The Group's close
collaboration with Aptamer Group strengthens our position in protecting public
health, especially in water purity, through innovative detection technology."

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

Reach announcement

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFLIASIILIE